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Abstract 37 
Physical inactivity and disuse are major contributors to age-related muscle loss. Denervation 38 
of skeletal muscle has been previously used as a model to investigate muscle atrophy with 39 
disuse. Although gene regulatory networks that control skeletal muscle atrophy after 40 
denervation have been established, the transcriptome in response to recovery of muscle after 41 
disuse and the associated epigenetic mechanisms that may function to modulate gene 42 
expression during skeletal muscle atrophy or recovery have yet to be investigated. We report 43 
that silencing the tibialis anterior muscle in rats with Tetrodotoxin (TTX), administered to the 44 
common peroneal nerve, resulted in reductions in muscle mass of 7%, 29% and 51% with 45 
corresponding reductions in muscle fibre cross-sectional area of 18, 42, 69% following 3, 7 46 
and 14 days of TTX respectively. Importantly, 7 days of recovery, during which rodents 47 
resumed habitual physical activity, restored muscle mass from a reduction of 51% after 14 48 
days TTX to a reduction of only 24 % compared to sham control. Returning muscle mass to 49 
levels observed at 7 days TTX administration (-29%). Transcriptome wide analysis 50 
demonstrated that 3,714 genes were differentially expressed across all conditions at the 51 
significance level of P ≤ 0.001 following disuse induced atrophy. Interestingly, after 7-days 52 
of recovery, the expression of genes most changed during TTX had returned towards the 53 
sham control. The 20 most differentially expressed genes following microarray analysis were 54 
identified across all conditions and cross-referenced with the most frequently occurring 55 
differentially expressed genes between conditions. This gene subset included Myogenin 56 
(MyoG), Hdac4, Ampd3, Trim63 (MuRF1) and Chrna1. Expression of these genes and 57 
Fboxo32 (MAFbx), because of its previously identified role in disuse atrophy with Trim63 58 
(MuRF1), were confirmed by qRT-PCR and DNA methylation of their promoter regions 59 
analysed by PCR and pyrosequencing. MyoG, Trim63 (MuRF1), Fbxo32 (MAFbx) and 60 
Chrna1 showed significantly decreased DNA methylation at key time points after disuse-61 
induced atrophy that corresponded with significantly increased gene expression. Importantly, 62 
following TTX cessation and 7 days of recovery, there was marked increase in DNA 63 
methylation profiles of Trim63 (MuRF1) and Chrna1 back toward to control levels. This also 64 
corresponded with the return of gene expression in the recovery group back to baseline 65 
expression seen in sham-operated controls. To our knowledge this is the first study to 66 
demonstrate that skeletal muscle atrophy, in response to disuse, is accompanied by dynamic 67 
epigenetic modifications that correlate with alterations in gene expression, and that these 68 
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epigenetic modifications and gene expression profiles are reversible following the return to 69 
normal activity of skeletal muscle.  70 
Introduction  71 
Skeletal muscle is the most abundant tissue in the mammalian body and therefore 72 
maintenance of its structure and function are important to health across the lifespan.  The 73 
global maintenance of skeletal muscle mass is governed by the fine balance between muscle 74 
protein synthesis and degradation. Skeletal muscle undergoes rapid loss (atrophy) during 75 
disuse and inactivity (1-4), catabolic/inflammatory disease states such as cancer cachexia (5, 76 
6), sepsis (7), chronic heart failure (8), obesity (9) and also with denervation following, for 77 
example, spinal cord injury (10) or during ageing (sarcopenia) (11). In order to investigate 78 
the underlying time course and mechanisms of skeletal muscle atrophy, models such as 79 
denervation via nerve section (12), tetrodotoxin (TTX) injection (13), limb suspension (14), 80 
space flight (15) and chronic overuse (16, 17) have been implemented. Within these models, 81 
large alterations in gene regulatory networks may orchestrate the altered balance between 82 
protein synthesis and degradation during muscle wasting (18). Under such conditions, these 83 
regulatory networks are altered to favour the breakdown of skeletal muscle proteins 84 
predominantly via the ubiquitin-proteasome pathway (19-21). While gene regulatory 85 
networks controlling skeletal muscle atrophy have been somewhat elucidated, the role of 86 
epigenetic alterations to modulate gene expression during skeletal muscle atrophy has 87 
received less attention. Furthermore, there are few studies investigating the transcriptomic 88 
and epigenetic change underlying the recovery of skeletal muscle following a return to 89 
normal physical activity after a period of disuse.  90 
 91 
Epigenetic control of gene expression occurs primarily as a result of modification to DNA or 92 
chromatin/histones, as well as post-transcriptional modification of RNA (22). It has recently 93 
been suggested that denervation induced atrophy results in differential expression of genes 94 
associated with chromatin remodelling (23). Recent in-vitro evidence also suggests that 95 
epigenetic mechanisms may influence regeneration and myotube atrophy (24). Skeletal 96 
muscle cells that have encountered the atrophic stimulus of the inflammatory cytokine TNF-97 
 during their early proliferative life are more susceptible to TNF-  later in their 98 
proliferative lifespan, and show impaired differentiation and regeneration compared to 99 
matched, untreated controls (24). Importantly, in this study, a retention of DNA methylation 100 
of the myogenic regulatory factor, myoD was evident over 30 population doublings in the 101 
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muscle cells receiving a single acute (24 hr) cytokine stress in early life (24). This study 102 
therefore points to a potentially important epigenetic mechanism underlying susceptibility to 103 
loss of muscle mass (25). Further, recent studies investigating 44 muscle specific genes 104 
reported that where low methylation occurred gene enhancer activity increased (26). Despite 105 
this, it has not been confirmed in-vivo whether the modulation of gene expression via DNA 106 
methylation is a mechanism that regulates skeletal muscle disuse atrophy.  107 
 108 
To induce atrophy in the present study, we used tetrodotoxin (TTX) to silence the nerve to 109 
evoke disuse-induced muscle atrophy. Tetrodotoxin inhibits the firing of action potentials by 110 
binding to the voltage-gated sodium channel in nerve cell membranes, blocking the 111 
throughput of sodium ions. Therefore, the muscles innervated by the blocked nerve cannot be 112 
activated to contract (27). This model has the great advantage over nerve section, in that TTX 113 
causes a complete but reversible block of sodium channels and hence reversible nerve and 114 
muscle inactivity. In this study, in order to investigate both disuse and recovery, TTX was 115 
delivered over a pre-set period after which normal nerve activity resumed. Following nerve 116 
silencing, DNA microarray technology was used to investigate the temporal genome wide 117 
transcript expression profiles associated with progressive atrophy at 3, 7 and 14 days of 118 
disuse. The nerve block was then released, habitual activity resumed, and gene expression 119 
profiles were monitored following 7 days of recovery. Finally, DNA methylation within the 120 
promoter regions of genes was measured via pyrosequencing for genes that showed (via 121 
microarray and confirmatory qRT-PCR) the most significant alterations in expression across 122 
all conditions, and were most frequently differentially expressed when comparing between 123 
conditions. The aim of the investigation was therefore to elucidate the epigenetic control of 124 
gene expression after disuse atrophy and a return to normal physical activity in skeletal 125 
muscle, we hypothesised that: 1) disuse atrophy is controlled by differential DNA 126 
methylation that enhances or suppresses gene expression, and; 2) that DNA methylation and 127 
gene expression adaptations are transient and dynamic and therefore reversible, as normal 128 
muscle activity resumes.   129 
 130 
Materials and Methods 131 
 132 
Animals 133 
Ethical approval was obtained and experimental procedures were conducted under the 134 
permissions within a project licence granted under the British Home Office Animals 135 
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(Scientific Procedures) Act 1986. Male Wistar rats weighing between 350g – 450g were 136 
housed in controlled conditions of 20 C, 45% relative humidity with food and water 137 
available ad libitum. Animals were assigned to five groups including one control group, and 138 
three Tetrodotoxin exposed groups (TTX) for periods of 3, 7 and 14 days, including a 14 139 
days TTX exposure plus 7-day active recovery group (recov). Experimental groups are 140 
detailed below and represented schematically in Figure 1. 141 
 142 
Experimental Groups 143 
The left common peroneal nerve was exposed to TTX over pre-set time courses. Groups (n = 144 
6) consisted of 3-day (3d), 7-day (7d), 14-day (14d) TTX exposure and 14d TTX followed by 145 
7d natural active recovery (recov). In order to control TTX exposure, a mini-osmotic pump 146 
(Mini Osmotic Pump 2002, Alzet, Cupertino CA, USA) was implanted subcutaneously in the 147 
scapular region of animals in the TTX conditions. Delivery tubes were subcutaneously 148 
channelled to a silicone rubber cuff carefully placed around the common peroneal nerve of 149 
the left hind limb. Implantation was performed in-house as a modification of a published 150 
design (28). The osmotic pump efficiently delivered 0.5 μl/hr of TTX (350 μg/ml in sterile 151 
0.9 % saline) to the nerve cuff allowing the common peroneal nerve to be exposed to TTX, so 152 
that the ankle dorsiflexor muscles (tibialis anterior and extensor digitorum longus) were 153 
silenced but normal voluntary plantarflexion was maintained. The general welfare and 154 
mobility of the group-housed rats was minimally affected. Correct assembly and loading of 155 
the osmotic pump and nerve cuff was planned so that TTX administration would terminate 156 
after 14d, allowing recovery of hind-limb function from day 14 to day 21 within the 14d TTX 157 
+ 7d recovery group.  158 
 159 
Morphology and Histology for Muscle Size (Mass and Cross-Sectional Area)  160 
At the end of each experimental time course, all animals were humanely euthanized with 161 
increasing CO2 concentration and cervical dislocation, in accordance with the Animals 162 
(Scientific Procedures) Act 1986. For morphological and histological purposes, muscle was 163 
harvested from control and experimental groups (n = 6), weighed, divided into pieces and a 164 
transverse portion from the mid-belly of the muscle was frozen in melting isopentane, 165 
cryostat sectioned (~ 10 μm) and stained with heamatoxylin and eosin (H&E). For each 166 
muscle sample, five pictures were obtained at random. Using ImageJ 1.45i software 167 
(https://imagej.nih.gov/ij/), each photograph was overlaid with an 8  8 grid in to make an 168 
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unbiased selection of fibres. Ten fibres were selected for counting for each field of view at 169 
the first ten intersections of the grid that fell within a fibre. The magnification of each section 170 
was calibrated from an image of a stage graticule. Cross sectional area (CSA) was estimated 171 
from precise diameter measurements taken by selecting two points across the minimum 172 
diameter, and assuming a circular cross section. Mean tibialis anterior (TA) mass for all 173 
control and experimental groups was expressed as a percentage of whole animal body mass 174 
(428 ± 45 g) to normalise for inter-individual differences in animal size (n = 6) (Figure 3). 175 
Mean cross sectional area (CSA) of the TA muscle fibre was expressed as a percentage 176 
change from untreated contralateral control limb for each animal (n = 6) (Figure 3). All data 177 
are presented as mean ± standard deviation, unless stated otherwise. 178 
Transcriptome Analysis  179 
To compare genome-wide transcript expression from 3, 7, 14-d TTX and 14-d TTX plus 7-d 180 
recovery (n = 4 for each group), microarray analyses were conducted. Untreated control 181 
samples were also used for quality control of microarray analysis, and excluded from final 182 
analysis. Frozen muscle samples were sent to AROS Applied Biotechnology, where RNA 183 
was isolated via AROS Standard Operating Procedures. Over 30,000 rat transcripts and 184 
28,000 variants were examined via Affymetrix GeneChip® Rat Genome 230 2.0 Array 185 
(Affymetrix, High Wycombe, UK). Raw data files (.CEL) were normalised via the MAS 5.0 186 
signal method (29, 30) and .CHP files were subsequently analysed for significantly 187 
differential gene expression from microarray data (Transcriptome Analysis Console (TAC), 188 
Affymetrix, High Wycombe, UK).  TAC software was used to create hierarchical clustering 189 
heatmaps of the most differentially expressed genes.  190 
RNA Isolation and Primer Design for qRT-PCR 191 
RNA was extracted from frozen muscle tissue (n = 6 for all sample groups) and frozen in 192 
RNA storage solution (Qiagen, Manchester UK). Samples (~ 20 mg) were immersed and 193 
homogenized in TRIzol (Thermo Fischer Scientific, UK) and RNA extracted according to 194 
manufacturer’s instructions. Quantities and quality of RNA were assessed by 260/280 UV 195 
spectroscopy (Fisher, Rosklide, Denmark). Isolated RNA produced an average 260/280 ratio 196 
of 1.99 (± 0.02). Primers were designed with the Primer blast/designer (National Centre for 197 
Biotechnology Information/NCBI). All designed primers were between 20 and 21bp in length 198 
and where possible had a GC content of 50-55%. The software programme ‘netprimer’ 199 
predicted the efficiency of the primer products, estimating the probability of primer dimer or 200 
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hairpin formation. Primers were manufactured by Sigma and resuspended in either TE buffer 201 
or RNA free water (Sigma) as a 100 μM stock suspension. Details of primer assays are given 202 
in Table 1.  203 
 204 
Quantitative Reverse Transcription Real Time Polymerase Chain Reaction (qRT-PCR) 205 
Quantitative real time polymerase chain reaction (qRT-PCR) was performed by using either 206 
HotStart Taq Master Mix Kit (Qiagen, Manchester, UK) and an iQ5 Thermocycler (BioRad) 207 
or QuantiFast™ SYBR® Green RT-PCR one-step kit on a Rotorgene 3000Q (Qiagen, 208 
Manchester, UK). cDNA synthesis for subsequent PCR on the iQ5 Thermocycler was 209 
performed as follows: 1 μg of RNA was diluted in 12 μl of RNA free water and 1 μl of oligo 210 
dT primer (Invitrogen) was incubated at 70 C for 10 mins and subsequently snap cooled on 211 
ice to enable binding of the primer. A reaction mix (4 μl of 5X buffer, 2 μl of dithiothreitol, 1 212 
μl of deoxynucleotide triphosphates) was added per RNA samples and incubated at 42 C for 213 
two mins. 1 μl of Superscript II Reverse Transcriptase (Invitrogen) was then added and the 214 
reaction mix incubated for a further 50-mins at 42 C. This reaction was then inhibited by 215 
heating to 70 C for 15 mins. As a control, reactions were prepared in parallel to those 216 
described above for each RNA sample, without the inclusion of the reverse transcriptase 217 
enzyme so that mRNA would not be reverse transcribed into cDNA. These negative control 218 
primers were used to confirm that the products amplified by PCR were indeed derived from 219 
cDNA. For qRT-PCR using HotStart Taq Master Mix Kit on the iQ5 Thermocycler, reactions 220 
were as follows; 3 μl cDNA, 15 μl Hotstar Taq Master Mix, 1.5 μl each of forward and 221 
reverse primer and 9 μl of RNAse-free water, totalling 30 μl reactions. For qRT-PCR using 222 
QuantiFast™ SYBR® Green RT-PCR one-step kit on a Rotorgene 3000Q, reactions were as 223 
follows; 9.5 μl RNA sample (7.3 ng/μl = 70 ng total RNA in the reaction), 0.15 μl forward 224 
primer, 0.15 μl reverse primer, 0.20 μl of Reverse transcriptase (RT) mix and 10 μl of 225 
SYBR
® 
Green buffer (QuantiFast™ SYBR® Green RT-PCR one-step kit, Qiagen, 226 
Manchester, UK), totaling 20 μl. For QuantiFast™ SYBR® Green RT-PCR one-step kit, 227 
reverse transcription cycles were performed in the same tube/reaction prior to PCR, as 228 
follows: hold 50 C for 10-min (reverse transcription/cDNA synthesis), followed by 95 C 229 
for 5-min (transcriptase inactivation and initial denaturation step), before 40 PCR cycles of; 230 
95 C for 10 sec (denaturation), 60 C for 30 sec (annealing and extension). Finally, melt 231 
curve analyses were performed to identify any primer dimer formation or non-specific 232 
amplification. All melt curves produced single reproducible melt temperatures across all 233 
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experimental samples. All relative mRNA expression was quantified using the comparative 234 
Ct (
Ct
) method (31) against a known reference gene of RPIIb (polr2b) and/or Rn18s. 235 
Average Cycle threshold (Ct) values for RPIIb and Rn18s were 20.08 (±0.59) and 15.80 236 
(±0.39) respectively across all experimental conditions. 237 
DNA isolation and Bisulfite Conversion  238 
To elucidate the methylation profiles, DNA was extracted from frozen muscle tissue using a 239 
commercially available DNA isolation kit (DNA Blood and Muscle Kit, Qiagen, Manchester, 240 
UK), according to that manufacturer’s instructions. For methylation analysis via high 241 
resolution melt polymerase chain reaction (HRM-PCR) (see methods below), bisulfite 242 
conversion of 2 μg of DNA was performed using InnuConvert All-in-One Bisulfite 243 
Conversion kits (AJ Innuscreen GmbH, Berlin, Germany). For DNA methylation by PCR and 244 
pyrosequencing (see methods below), 500 ng of DNA was bisulfite converted using a Zymo 245 
Research EZ Methylation Kit (Cat. D5002 or D5004).  246 
DNA methylation by Polymerase Chain Reaction and Pyrosequencing 247 
Assays for pyrosequencing were purchased from epigenDX (Hopkinton, MA, USA) 248 
(summarised in Table 2 and Fig. 2) Following bisulfite conversion, PCR reactions were 249 
designed depending on the specific DNA methylated region of interest and the size of the 250 
product, as per manufacturer’s instructions. However, a typical reaction was performed as 251 
follows; 3 μl of 10X PCR buffer (containing 15 mM MgCl2), 0.2 μl of 10 mM dNTPs, 1.8 μl 252 
of 25 mM MgCl
2
, 0.6 μl of 10 mM dNTPs, 0.15 μl HotStar Taq Polymerase, 1 µl of bisulfite 253 
treated DNA and 0.2 μM of forward and reverse primer (Table 2). One primer was biotin-254 
labeled and HPLC purified in order to facilitate purification of the final PCR product using 255 
sepharose beads. Following an initial denaturation incubation at 95°C for 15-min, 45 cycles 256 
of denaturation at 95°C for 30 s; 63°C for 30 s (annealing), 68°C for 30 s (extension) were 257 
performed, with all PCR cycles followed by a final 5 minutes at 68°C. PCR products were 258 
then bound to Streptavidin Sepharose HP (GE Healthcare Life Sciences), after which the 259 
immobilized PCR products were purified, washed, denatured with a 0.2 μM NaOH solution 260 
and rewashed using the Pyrosequencing Vacuum Prep Tool (Pyrosequencing, Qiagen), as per 261 
the manufacturer’s instructions. Following annealing with 0.5 μM sequencing primer, the 262 
purified single stranded PCR products were then sequenced using the PSQ96 HS System 263 
(Pyrosequencing, Qiagen) following the manufacturer’s instructions. The methylation status 264 
of each CpG site was determined individually as an artificial C/T SNP using QCpG software 265 
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(Pyrosequencing, Qiagen). The methylation level at each CpG site was calculated as the 266 
percentage of the methylated alleles divided by the sum of all methylated and unmethylated 267 
alleles. The mean methylation level was calculated using methylation levels of all measured 268 
CpG sites within the targeted region of each gene. Each experiment included non-CpG 269 
cytosines as internal controls to detect incomplete bisulfite conversion of the input DNA. In 270 
addition, a series of unmethylated and methylated DNA strands were included as controls 271 
after each PCR. Furthermore, PCR bias testing was performed by mixing unmethylated 272 
control DNA with in vitro methylated DNA at different ratios (0%, 5%, 10%, 25%, 50%, 273 
75%, and 100%), followed by bisulfite modification, PCR, and Pyrosequencing analysis. All 274 
supporting information for gene assays, including assay sequence, chromosomal CpG island 275 
locations, position from ATG start codon and transcriptional start site and CpG number are 276 
given in Table 2 and Fig. 2.  277 
 278 
High Resolution Melting Polymerase Chain Reaction (HRM-PCR) for Total DNA 279 
Methylation 280 
HRM-PCR for CpG methylation was performed as previously described (24). Briefly, 20 ng 281 
DNA was subjected to HRM-PCR using EpiTect HRM-PCR kits and Rotorgene 3000Q 282 
(Qiagen, Crawley, UK) with Rotorgene software (Hercules, CA, USA). All primer 283 
concentrations for gene CpG assays and EpiTect HRM master mix volumes were used in 284 
accordance with the manufacturer’s instructions. HDAC4 (Qiagen) was designed to amplify a 285 
product length of 140 to 190 bp (see Table 3). PCR cycles were performed as follows; 10 s at 286 
95 °C (denaturation), 30 s at 55 °C (annealing), 10 s at 72 °C (extension) for a maximum of 287 
55 cycles. Following PCR, a high-resolution melt (HRM) analysis was performed with 0.1 °C 288 
increments from 65 to 95 °C. Fluorescence versus melt temperature was used to create a 289 
standard curve using rat methylated DNA standards representing 100, 75, 50, 25, 10, 5 and 0 290 
% methylation. All samples were run in duplicate normalised to 0 % methylated control and 291 
averaged to produce a single curve. The relationship between the area under the curve, 292 
determined via each standard curve, and the corresponding percentage methylation curve of 293 
specific gene loci was determined via the best fitting fourth-order polynomial relation. This 294 
relationship was subsequently used to quantify the % methylation from the integrated raw 295 
melt curves of experimental samples. The calculations were performed using a Python-based 296 
program, MethylCal, developed for this purpose in-house (used previously in (24)).  297 
Statistical Analyses  298 
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All statistical analyses of morphological data were performed via either; i) software R: A 299 
Language and Environment for Statistical Computing, version 2.13.1 (www.R-project.org) 300 
or, ii) a statistical package for the social sciences software for Microsoft (SPSS, version 22.0, 301 
SPSS Inc, Chicago, IL). Morphological (muscle mass and CSA) comparisons between 302 
experimental and control conditions were assessed via a one-way between groups ANOVA. 303 
Microarray data was analysed for statistical comparisons via one-way between groups 304 
ANOVA within the TAC software. Targeted qRT-PCR was analysed using a one-way 305 
between groups ANOVA (with Tukey post-hoc tests). DNA methylation data sets were 306 
analysed using a two-way between groups ANOVA (with Tukey post-hoc tests) allowing 307 
comparisons of experimental conditions and individual CpG islands. A follow up one-way 308 
ANOVA between CpG islands at each experimental condition was used to identify 309 
significant differences in DNA methylation status of each CpG island within the same 310 
experimental condition. Finally, T-tests were used to identify significant differences between 311 
CpG methylation in the experimental conditions and control. All statistical analysis for DNA 312 
methylation was performed on absolute values, with figures representing data as mean fold 313 
change (± standard deviation) to relevant control. Differences were considered statistically 314 
significant when P ≤ 0.05. 315 
 316 
RESULTS 317 
 318 
Skeletal Muscle Disuse and Recovery evokes Considerable yet Reversible Muscle 319 
Atrophy  320 
Exposure to TTX produced an average of 7.0 ± 2.4% loss in TA muscle mass at 3-d, 28.7 ± 321 
5.1% at 7-d and 50.7 ± 2.7% loss following 14-d that resulted in statistical significance at all 322 
time points versus the unoperated right TA (P < 0.001; Fig. 3) and a significant difference 323 
between paired comparisons of 3 and 7-d, 3 and 14-d, 7 and 14-d (P < 0.001). After 14 d 324 
TTX exposure followed by 7d cessation in recovery group, muscle mass significantly 325 
recovered by 51.7% vs. 14 d of denervation (P = 0.001; Fig. 3). Seven days of recovery did 326 
not completely restore muscle mass, as muscle mass was still significantly lower than control 327 
(P < 0.001; Fig. 3), total muscle mass was equivalent to levels at 7-d TTX administration, 328 
suggesting that rates of loss over 7-d were similar to rates of recovery. We therefore report 329 
significant skeletal muscle atrophy of the TA muscles with disuse and a 51.7% recovery of 330 
muscle mass following 7-day cessation of the TTX administration and return of normal 331 
habitual physical activity. 332 
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 333 
Exposure to TTX produced a progressive reduction in mean muscle fibre CSA of 17.95 ± 334 
12.06% at 3-d, 42.09 ± 6.17% at 7d and 68.94 ± 2.97% at 14-d of TTX exposure, with 7-d 335 
and 14-d TTX exposure being significantly reduced versus the control (P = 0.003; P < 0.001, 336 
respectively; Fig. 4). Similarly, to TA muscle mass, upon TTX cessation, the 14-d TTX + 7-d 337 
recovery group muscle CSA significantly recovered compared to 14-d TTX alone, with an 338 
increase of 62.6% in CSA compared with 14-d TTX alone (p = 0.002; Fig 4). Therefore, 339 
there was significant atrophy of individual skeletal muscle fibres in the TA muscles following 340 
denervation and a 51.7% recovery of muscle mass and 62.6% recovery of muscle CSA 341 
following 7-day cessation of the TTX administration and normal habitual physical activity. 342 
 343 
Gene Expression Microarrays Identify Important Gene Regulatory Networks involved 344 
in Muscle Atrophy and Recovery.  345 
After confirming significant reduction in muscle mass, the temporal transcriptome profile 346 
accompanying muscle atrophy was investigated (n=4). The dendogram from hierarchical 347 
clustering of probe sets across the genome identified 3,714 genes that showed highly 348 
significant differential expression with a P value of   ≤ 0.001 (Fig. 5a).  It also demonstrated 349 
that there was a strong clustering of data for the 3, 7 and 14-d TTX groups, which were 350 
clearly separated from another identified clustering of data consisting of the sham-operated 351 
control and the recovery groups (Figure 5a and Supp. 1a). This suggested that disuse-induced 352 
atrophy evoked a considerable characteristic change in expression of a large number of genes 353 
that were returned back to levels in the sham controls on cessation of the nerve block in the 354 
recovery group (Fig. 5a). Despite the top 20 genes showing recovery back to control sham 355 
levels, 846 genes were still significantly differentially expressed (P < 0.05) in the recovery 356 
group compared to sham control (Supp. 1i). Further analyses were performed using 357 
unsupervised hierarchical clustering of the top 20 most differentially expressed genes (Fig. 5b 358 
and Supp. 2). This analysis confirmed that these top 20 genes most differentially expressed in 359 
TTX groups returned back towards sham control following 7 days of recovery. Furthermore, 360 
the top 500 genes that were upregulated by TTX administration could be grouped into three 361 
distinct clusters based on their temporal behaviour: An immediate and sustained increase in 362 
expression (Fig. 5c), a delayed but progressive increase in expression (Fig 5d), and finally an 363 
immediate increase in expression that declined over the time course (Fig 5e), suggesting that 364 
dynamic disuse and co-ordinated gene expression occurred across a large number of genes as 365 
a result of disuse and the return back towards control levels in the recovery group.   366 
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 367 
This suggested that disuse-induced atrophy evoked a considerable characteristic change in 368 
expression of a large number of genes that were returned back to levels in the sham controls 369 
on cessation of the nerve block in the recovery group (Fig. 5a). Further analyses were 370 
performed using unsupervised hierarchical clustering of the top 20 most differentially 371 
expressed genes (Fig. 5b and Suppl. 1b). This analysis confirmed that these top 20 genes 372 
most differentially expressed in TTX groups returned back towards sham control following 7 373 
days of recovery. Furthermore, the top 500 genes that were upregulated by TTX 374 
administration could be grouped into three distinct clusters based on their temporal 375 
behaviour: An immediate and sustained increase in expression (Fig. 5c), a delayed but 376 
progressive increase in expression (Fig 5d), and finally an immediate increase in expression 377 
that declined over the time course (Fig 5e), suggesting that dynamic disuse and co-ordinated 378 
gene expression occurred across a large number of genes as a result of disuse and the return 379 
back towards control levels in the recovery group.   380 
 381 
Regulated Genes Identified by Microarray and Ranked by Significance of Change
 
382 
Transcriptome wide data was analysed to compare between conditions in 6 pairwise 383 
comparisons (Sham vs. 3d (Suppl. 1c), 7d (Suppl. 1d), 14d (Suppl 1e) and Recovery vs. 3d 384 
(Suppl. 1f), 7d (Suppl. 1g), 14d (Suppl. 1h)) to identify the genes that were among the most 385 
significantly affected in the experimental groups. Trim 63 (MuRF1), Myogenin (MyoG) and 386 
Ampd3 were identified as being the most frequently occurring genes most differentially 387 
expressed across these paired comparisons, that also appeared in the top 20 differentially 388 
expressed genes across all conditions (Fig. 5b and Supp. 1b). Ampd3 appeared in 4 out of 6 389 
of these paired comparisons (Supp 1c, 1f, 1g, 1h). Previous studies have also suggested 390 
overexpression of Ampd3 increases protein degradation in C2C12 myotubes (32), and thus 391 
we sought to further elucidate its transcriptional and epigenetic role in denervation induced 392 
atrophy in the present manuscript. The E3 ubiquitin ligase, Trim 63, appeared in 3 out of 6 393 
paired comparisons (Suppl. 1c, 1f, 1h) and has been previously strongly associated with 394 
muscle atrophy in-vitro and in-vivo (33-37), as is its protein family member, Fbxo 32 395 
(Mafbx). We therefore extended the analysis of this change by qRT-PCR and loci-specific 396 
pyrosequencing for DNA methylations role in TTX-induced atrophy and recovery. The 397 
muscle specific basic helix-loop-helix (bHLH) myogenic regulatory factor, MyoG, was also 398 
identified in 3 out of 6 paired comparisons (Suppl. 1c, 1d, 1e) and has also previously been 399 
identified as a key transcript in regulating denervation-dependent muscular atrophy in rodent 400 
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models (38). Importantly, the class II histone deacytelase (Hdac 4), also appeared within the 401 
top 20 most statistically differentially expressed genes across all probe sets (Fig. 5b, Suppl. 402 
1b), and was the most statistically differentially expressed gene when comparing sham 403 
control to 3D TTX atrophy probe sets (Suppl. 1c). Hdac 4 is a known upstream regulatory 404 
factor of MyoG activity (36, 39), and thus both Hdac 4 and MyoG genes were identified as 405 
warranting further targeted analysis. Additional NMJ associated genes that were significantly 406 
altered and appeared in the top 20 most differentially expressed genes included the 407 
acetylcholine receptor subunit alpha 1 (Chrna1) (Figure 5b). This gene also appeared in 2 out 408 
of 6 paired comparisons of most differentially expressed genes (Suppl. 1d, 1e). Chrna1 plays 409 
a crucial role in acetylcholine binding and channel gating activity, within the neuromuscular 410 
junction pathway (40) and has been previously been identified via transcriptome analysis as 411 
the most differentially expressed gene in skeletal muscle loss observed in age related muscle 412 
loss/denervation (41). After identification of key gene transcripts, quantification of gene 413 
expression was elucidated via follow up qRT-PCr in order to confirm and further profile the 414 
transcriptional responses and DNA methylation analyses were performed with 415 
pyrosequencing to assess the status of the genes promoter region in response to disuse muscle 416 
atrophy and recovery. 417 
 418 
Changes in Gene Expression Following Disuse Induced Atrophy Are Returned to 419 
Control Levels Following Recovery 420 
Confirmation of microarray gene expression by qRT-PCR demonstrated that of MyoG, 421 
Hdac4 Trim63 and Fbxo32 significantly increased at 3d of TTX exposure compared to 422 
control (P < 0.05), with Hdac4 and Fbxo32 (Fig. 6a) remaining elevated at 7d of TTX 423 
exposure. By 14d the mean levels for Hdac4, MyoG, Trim63 and, Fbxo32 were not 424 
significantly different, suggesting elevation predominately at 3-7 days of these genes in 425 
response to disuse. In contrast, while significant changes in Ampd3 expression were not 426 
detected (Fig. 6a), Chrna1 expression was significantly elevated at 3, 7, and 14 days (177.5-427 
fold increase vs. control; P = 0.016, Figure 6a). Following TTX cessation and 7 days of 428 
recovery; Hdac4, MyoG, Trim63, Fbxo32 and Chrna1 gene expression had all returned to 429 
Sham control levels, as suggested above in the microarray data.  430 
 431 
DNA Methylation Regulates Gene Expression involved in Disuse Induced Atrophy and 432 
Recovery 433 
Loci-specific pyrosequencing of individual CpG islands within gene promoters revealed 434 
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significant alterations in the DNA methylation of the key genes identified following 435 
microarray analysis and confirmatory qRT-PCR, that corresponded with significant increases 436 
in gene transcription. Following 3-d TTX exposure, there was a significant reduction 437 
(P=0.011) in DNA methylation of the MyoG gene promoter (Fig. 6b) and a concomitant 438 
significant increase (P=0.011) in myoG gene expression (Fig. 6a), both of which then 439 
returned towards baseline levels over the remaining 14 days (all gene expression/DNA 440 
methylation overlap relationships are schematically represented in Fig 6c). The DNA 441 
methylation profile of the Chrna1 gene promoter progressively decreased relative to control, 442 
with 7-d and 14-d TTX treatment attaining significance versus sham controls (P = 0.035; P < 443 
0.001, respectively). This corresponded with the increased expression of this gene over the 444 
14-day denervation period (Fig. 6a and 6c). Like Chrna1, Trim63 displayed significant 445 
reduction in methylation at 7-d and 14-d of TTX exposure (P = 0.035; P < 0.001, 446 
respectively), (Fig. 6b and 6c) which coincided with a stable increase in mRNA expression at 447 
the same time points (Fig. 6a and 6c). Fbxo32 showed a decreasing trend in DNA 448 
methylation at specific time points, attaining significance at 14-d TTX exposure (P = 0.021) 449 
(Fig. 6b, 6c), with gene expression data reporting significant increases at 3-d (P = 0.037) and 450 
7-d (P = 0.038) atrophy (Fig 6a, 6c). Importantly, following TTX cessation there was a 451 
recovery in the DNA methylation profile in Trim63, Fbxo32 and Chrna1 returning to sham 452 
control levels (P > 0.05). This was in conjunction with an observed recovery of gene 453 
expression of the same genes upon TTX cessation (Fig 6c). We found no differences in DNA 454 
methylation for Ampd3 following TTX administration or recovery (Fig. 6b). Furthermore, 455 
following initial total % of methylation within the total amplicon/product via HRM PCR for 456 
Hdac4 we were unable to identify methylation above that of the 0% methylation control for 457 
all conditions and therefore pyrosequencing for loci specific DNA methylation was not 458 
performed for Hdac4.  459 
 460 
Discussion 461 
Summary  462 
The aim of this investigation was to elucidate the epigenetic control of gene expression 463 
following skeletal muscle disuse atrophy following 3, 7 and 14 days of nerve block with 464 
TTX. Firstly, we found a 7, 29 and 51% loss of muscle at 3,7 and 14 days of disuse, with 7 465 
days of recovery resulting in a 51.7% restoration of total muscle mass lost after 14 days of 466 
disuse. Muscle mass was therefore similar after 7 d of disuse or 14d of disuse followed by 7 d 467 
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of normal activity. Muscle atrophy was further confirmed with fibre cross-sectional area data, 468 
in which a similar pattern of progressive loss was observed of 18, 42, 69% following 3, 7 and 469 
14 days of TTX respectively. Seven days of recovery, restored 63% of muscle cross-sectional 470 
area vs. 14-day disuse atrophy alone. Our original hypothesis was supported, in that disuse 471 
atrophy was associated with reduced DNA methylation and enhanced expression of a sample 472 
genes whose expression was most affected by disuse and recovery. Both DNA methylation 473 
and gene expression were partially returned to baseline after 7 days of recovery from the 474 
nerve block. Importantly, following gene expression microarray analysis we found that 3,714 475 
genes were highly (P ≤ 0.001) significantly regulated in TTX groups, and that these genes 476 
were returned in the recovery group back towards levels observed in the sham control. 477 
Specifically, by identifying the top 20 most differentially expressed genes in atrophy and 478 
recovery groups, and cross referencing with the most frequently occurring significantly 479 
regulated genes for between group pairwise comparisons, we identified a key subset of 480 
influential genes MyoG, Hdac4, Trim63 (Murf1), Ampd3 and Chrna1. These genes, together 481 
with Fboxo32 (Mafbx) because of its previously defined role with Trim63 (Murf1) in muscle 482 
atrophy (discussed below), were then analysed via qRT-PCR to confirm microarray gene 483 
expression data for these genes as well as loci-specific DNA methylation of the promoter 484 
regions by pyrosequencing. All these genes (MyoG, Hdac4, Trim63/Murf1, Ampd3, Chrna1 485 
and Fboxo32/Mafbx) have been identified previously via transcriptome wide analysis of 486 
disuse atrophy following neuromuscular blocker α-cobrotoxin treatment (42). In this 487 
investigation, we showed novel data suggesting that MyoG, Trim63 (Murf1), Fbxo32 488 
(Mafbx) and Chrna1 had reduced DNA methylation at specific time points following disuse 489 
induced atrophy that corresponded with time dependent increases in gene expression. 490 
Importantly, following TTX cessation and 7 days of recovery during which normal habitual 491 
physical activity was resumed, there was a return of DNA methylation for Trim63, Fbxo32 492 
and Chrna1, back towards sham control levels. Importantly, this also corresponded with the 493 
return of gene expression back to that of baseline sham controls. As reduced DNA 494 
methylation within promoter or enhancer regions of genes can lead to enhanced gene 495 
expression because reduced methylation allows access for RNA polymerase to enable 496 
transcription (43), our data suggests that atrophy and recovery of skeletal muscle following 497 
disuse is associated with dynamic and transient epigenetic modifications that correspond with 498 
altered gene expression.  499 
 500 
  
 16 
Dynamic and Transient DNA Methylation following Atrophy and Recovery of Muscle Mass.  501 
Interestingly, 51.7% of total muscle mass loss after 14 days was restored following 7 days of 502 
recovery, yet importantly gene expression was returned fully to baseline after 7 days, 503 
suggesting, as perhaps would be expected due to the time required for transcription, 504 
translation and protein incorporation, a time lag between gene expression and physiological 505 
restoration of muscle mass. However, the findings in this study suggest that the reduced DNA 506 
methylation corresponding with increased gene expression of MyoG, Trim63 (MuRF1), 507 
Fbxo32 (MAFbx) and Chrna1 is a dynamic and transient event, in which decreases in DNA 508 
methylation at 3, 7 and 14 days of TTX-induced atrophy correspond with increases in gene 509 
expression, that in turn are returned back to baseline (Trim63/MuRF1) and Chrna1) within 510 
just 7 days after the removal of the TTX block. DNA methylation has previously been 511 
reported to be mitotically stable and as such, environmental factors were believed to be 512 
unable to induce significant alterations in DNA methylation at both acute and chronic time 513 
points (44). Furthermore, our previous data suggests that even following acute catabolic 514 
stress, DNA methylation can be stably retained across several population doublings of muscle 515 
cells in-vitro (24). However, we show here that DNA methylation does respond at a rate that 516 
allows for its participation in the adaptive control of gene expression, and adds further 517 
support to previous findings of transient alterations of skeletal muscle DNA methylation, for 518 
example following acute aerobic exercise (24, 45). Our data adds further support to previous 519 
findings of transient alterations of skeletal muscle DNA methylation. 520 
Although not identified in this study it will be important in future studies to investigate DNA 521 
methyltransferase activity. The de novo methyltransferases (DNMT 3a, 3b) are involved in 522 
the initial incorporation of methyl groups to cytosine residues and the creation of 5-523 
methylcytoseines (5-mC) to increase in DNA methylation. The maintenance DNA 524 
methyltransferase (DNMT 1) is involved in retaining the methyl tag onto the DNA strand 525 
(46). The dynamic and transient observation of DNA methylation in this study is suggestive 526 
of a high activity of DNMT 3a and 3b activity in which initial and rapid increases in DNA 527 
methylation is observed. However, we do not report significant retention of DNA 528 
methylation upon TTX cessation (14-d TTX + 7-d recovery), which would suggest that 529 
DNMT 1 has not maintained the methylation status of some of these genes beyond muscle 530 
recovery. It has previously been reported that increases in both types of DNMT is observed 531 
following a high-fat diet that induced increases in DNA methylation of 6,508 genes (47). 532 
Further work is needed to confirm similar findings in atrophying muscle, and to elucidate the 533 
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response of DNA methyltransferases upon the reversible insult. Finally, it would be 534 
important to undertake 14 d recovery in future experimentation to assess whether muscle 535 
mass can be returned fully back to baseline control levels and to examine the transcriptomic 536 
and epigenetic responses during this period. 537 
 538 
DNA Methylation Correlates with Important Changes in Skeletal Muscle Gene Expression 539 
following Disuse-Induced Atrophy and with the Return of Gene Expression to Baseline 540 
during Recovery. 541 
As suggested above: MyoG, Trim63, Fbxo32 and Chrna1 showed decreased DNA 542 
methylation following disuse-induced atrophy that corresponded with increased gene 543 
expression. Importantly, following TTX cessation and 7 days of recovery during which 544 
normal habitual physical activity was resumed, Trim63 and Chrna1, TTX-induced DNA 545 
methylation returned back to control levels as repression of gene expression recovered. The 546 
muscle specific basic helix-loop-helix (bHLH) transcriptional factor and member of the 547 
myogenic regulatory factors (MRFs), MyoG is commonly associated with the coordination of 548 
skeletal muscle development/myogenesis or skeletal muscle regeneration, and specifically the 549 
differentiation/fusion of skeletal muscle cells (48). Here we report a significant induction of 550 
gene expression for this transcription factor upon disuse-induced muscle atrophy. Because 551 
expression of this protein is usually associated with muscle regeneration, this may reflect a 552 
compensatory mechanism in an unsuccessful attempt to halt atrophy or to respond to a return 553 
of activity. The role of MyoG as a transcription factor has previously been linked with the 554 
regulation of the ubiquitin E3 ligases, Trim63 and Fbxo32 and associated muscle atrophy 555 
(34). Importantly, we provide novel data that suggests the DNA methylation profile of this 556 
transcript is altered in an inverse fashion to its mRNA expression. Indeed, at 3, 7 and 14 d we 557 
saw a significant reduction in MyoG DNA methylation and an increase in MyoG transcript 558 
expression. We therefore suggest that increased MyoG gene expression is regulated by 559 
reduced MyoG DNA methylation.  560 
 561 
Previous studies have also reported that MyoG gene expression is under the regulatory 562 
control of class II histone deacetylases (Hdacs) (34, 35). In partial support of this notion, we 563 
report a significant increase in class II Hdac, Hdac4 gene expression at 3 and 14-d of TTX 564 
exposure. We did not however, measure protein abundance or phosphorylation/ deacetylation 565 
status of Hdac4. Indeed, initial screening of Hdac 4 DNA methylation through HRM PCR 566 
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was unable to detect a notable change, with global gene percent methylation showing no 567 
greater values than 0 % methylated controls. Therefore, further work at the protein and 568 
histone level is needed to elucidate the epigenetic regulation of Hdac’s during periods of loss 569 
and recovery of muscle mass, as its altered gene expression following denervation does not 570 
seem to be controlled via DNA methylation. Furthermore, despite a return of MyoG gene 571 
expression back to control levels following 7-days recovery, DNA methylation continued to 572 
reduce in the recovery group. This shows that while reduced DNA methylation may have 573 
been important in increased gene expression during denervation induced atrophy, that DNA 574 
methylation was not controlling gene expression of MyoG during recovery.  575 
 576 
As suggested above, down-stream transcriptional targets of MyoG have also been shown to 577 
be highly induced during periods of muscle loss caused by denervation, immobilization and 578 
un-loading in rodents (49, 50). Trim63 is an E3 ubiquitin ligase and a member of the RING 579 
zinc finger family of proteins, that directs the polyubiquitination of proteins to target them for 580 
proteolysis. With catabolic stimuli, such as diabetes, cancer, denervation, unloading and 581 
glucocorticoid or cytokine treatment, its expression has consistently been shown to increase 582 
(50, 51). Previous studies have also suggested that upon denervation, northern blot analysis 583 
shows a significant increase in Trim63 and Fbxo32 following 3 days of muscle atrophy and 584 
continuing through to 7-d (50). Here, we report a significant increase in Trim63 and Fbxo32 585 
gene expression via qRT-PCR compared to control levels, at the same time as a reduction in 586 
DNA methylation. Importantly, this suggests an important role for epigenetic control of these 587 
ubiquitin ligases, in the resulting protein degradation and muscle loss observed in this study. 588 
We note that DNA methylation of both of these ubiquitin ligases increased back towards 589 
control levels with corresponding decreases in gene expression back towards the sham 590 
control level, suggesting that the reductions in DNA methylation during atrophy can be 591 
dynamically regulated.  592 
 593 
Further, the acetylcholine receptor subunit alpha 1 (Chrna1) makes up the majority of the 594 
muscle specific nicotinic acetyl choline receptor (nAchR) in adult skeletal muscle (52) and 595 
plays a crucial role in initiating the opening of the nAchR channel and the transfer of 596 
positively charged ions (53). Interestingly, we report a progressive increase in gene 597 
expression with a cumulative significant fold change exhibited by 14-d of TTX exposure. 598 
This alteration in gene expression is met with a parallel progressive reduction in DNA 599 
methylation with significance being observed at both 7 and 14-d following TTX-induced 600 
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atrophy. We report similar results to previous work (54), in which a significant increase in 601 
Chrna1 activity was also observed during sarcopenia induced atrophy. The nAchR are made 602 
up of 5 isoforms in human skeletal muscle, in with the subunit 1 alpha (Chrna1) is most 603 
dominant. These isoforms function to create an acetylcholine cluster around the 604 
neuromuscular central pore, in which they house target binding sites predominantly located at 605 
the alpha subunit in the extracellular domain near the N terminus. Upon contact of a chemical 606 
messenger to the binding site, all present subunits undergo a conformational change resulting 607 
in the nAchR channel opening (55). Upon denervation, however, no action potential 608 
messages are received and therefore it is possible that the reduced DNA methylation and 609 
increased transcriptional response (although we do not provide evidence of protein levels) 610 
may increase as a compensatory mechanism understood to increase the chance of forming 611 
new end plates. This response is equivalent to that seen after nerve section and it appears 612 
therefore to be a response to lack of activity rather than physical absence or damage to the 613 
nerve. Finally, upon TTX cessation and muscle recovery we report a return to control of the 614 
DNA methylation signature, coupled with a return to control of gene expression. Finally, as 615 
discussed above, genes such as MyoG, ubiquitin ligases, and Chrna1 have been identified as 616 
major regulators of muscle regeneration, protein degradation and function respectively. As 617 
the present study also identified these genes as being the most frequently occurring 618 
differentially expressed genes across comparisons using a non-selective transcriptome wide 619 
approach in a novel model of osmotically administered TTX-induced atrophy, further 620 
consolidates the important role of these genes in disuse atrophy.  621 
 622 
Conclusion 623 
MyoG, Trim63, Fbxo32 and Chrna1, but not Ampd3, showed decreased DNA methylation 624 
following disuse-induced atrophy that corresponded with increased gene expression and 625 
muscle atrophy. Importantly, following TTX cessation and 7 days recovery, there was 626 
increased DNA methylation of Trim63 and Chrna1 back toward to control levels, that also 627 
corresponded with the return of gene expression back to that of baseline in sham controls. 628 
Overall, this suggests that atrophy and recovery of skeletal muscle following disuse is in part 629 
controlled by dynamic and transient epigenetic regulation of gene expression.  630 
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Figure Legends 646 
 647 
Figure 1. Schematic Representation of the TTX Muscle Atrophy Model and Subsequent 648 
Muscle Sample Preparation for Morphological, Transcriptomic and Epigenetic 649 
Analysis. (A) Display of physiological location of tetrodotoxin administration pump. Inset 650 
shows; i) real image of osmotic pump location and assembly within the left hind limb of the 651 
rodent and, ii) provides a representation overview of the osmotic pump assembly, black lines 652 
show osmotic pump unit and delivery tube to nerve cuff unit and white line displays the 653 
synaptic nerve. (B) Muscle sample preparation for downstream analysis: Left (treated), right 654 
(untreated contralateral control), n=6. 655 
Figure 2. Gene map of CpG Islands for Loci Specific Pyrosequencing for Quantification 656 
of DNA Methylation Pyrosequencing. In descending order: Myogenin (myog), Fboxo32 657 
(MAFbx), Trim63 (MuRF1), Ampd3, Chrna1.  658 
 659 
Figure 3. Quantification of Muscle Atrophy (muscle mass) in-vivo following TTX-660 
Induced Nerve Block. Data shown for 3, 7 and 14 day treatment, and TTX nerve block + 7 661 
Day active recovery (7-d Recovery). Mean tibialis anterior (TA) mass for all control and 662 
experimental groups were expressed as a percentage difference of whole animal body mass 663 
(428 ± 45 g) to normalise for inter-individual differences in animal size (A), All data 664 
presented as mean ± standard deviation for n=6 in each condition. All statistical significance 665 
(via Pairwise Tukey post-hoc test) represented via *, with experimental conditions showing 666 
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significance relative to sham control, and 7d-recovery showing significance to 14-d TTX 667 
alone, indicated via #. All statistical values detailed in results text. 668 
Figure 4. Muscle Fibre Cross Sectional Area (CSA) after TTX-induced Atrophy and 669 
Recovery. Graphed figure represents Mean cross sectional area (CSA) of the TA muscle was 670 
expressed as a percentage change from untreated contralateral control limb for each animal. 671 
Haematoxylin and eosin stained sections of untreated (A) and treated (B) tibialis anterior 672 
muscle of control (i), 3-day TTX exposed (ii), 7-day TTX exposed (iii), 14-day TTX exposed 673 
(iv), 14-day TTX exposed with 7-day recovery (v). All statistical significance (via Pairwise 674 
Tukey post-hoc test) represented via *, with experimental conditions showing significance 675 
relative to sham control, and 7d-recovery showing significance to 14-d TTX alone, indicated 676 
via #. All statistical values detailed in results text. 677 
Figure 5. Genome Wide Transcript Expression Indicates Highly Dynamic Response to 678 
Progressive Muscular Atrophy that Returns to Sham Control Upon Muscle Recovery. 679 
Hierarchical clustering heatmaps of probe set expression across the rodent genome identifies 680 
3,714 genes that are highly statistically significantly (P value of ≤ 0.001) expressed across all 681 
conditions, with 3, 7 and 14D TTX atrophy being differentially expressed in comparison to 682 
sham control and 14D TTX + 7D recovery (A). This observation is confirmed in the top 20 683 
statistically differentially expressed genes across all conditions with distinct clustering 684 
occurring, suggesting significant differences in the expression of probe sets of 3, 7 and 14 685 
day TTX compared to sham control and 14 day TTX + 7D recovery (B). Top 500 most 686 
statistically differentially expressed genes grouped into three distinct clusters i) an immediate 687 
and sustained increase in expression (C), ii) delayed but progressive increase in expression 688 
(D), or iii) an immediate increase in expression that weakens over the time course (E). 689 
Notably, all gene clustering’s return to sham control expression levels upon TTX cessation 690 
and 7-d of recovery. 691 
 692 
Figure 6. Relative Fold Change of Gene Expression and DNA Methylation of a Subset of 693 
Identified Gene Transcripts Relative fold change in mRNA expression of genes MyoG, 694 
Trim 63, Fbxo 32, Chrna 1, Ampd 3 and Hdac 4 (A - in descending order). All genes are 695 
represented as mean ± standard deviations (n = 6), Ampd3 (n = 3). Statistically significant 696 
changes in fold difference compared to sham control group are indicated via *. Sham control 697 
group represented with triangle icon. All TTX treated groups represented with square icon 698 
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(A). Mean methylation data presented as relative fold change compared to control for genes: 699 
Myogenin, Trim 63, Fbxo32, Chrna 1 and Ampd 3 (B - in descending order). Mean 700 
percentage data (black column bars) are the average taken from each CpG island of the 701 
respective gene, analysed via loci-specific pyrosequencing. Individual CpG island 702 
methylation percentages are visualised as individual lines. DNA methylation data presented 703 
as mean ± standard deviation for n = 3. Statistically significant reductions compared to 704 
control group are indicated by use of *. §
 
indicates significant reduction compared to 7-d and 705 
14-d TTX atrophy. ✢ indicates a significant reduction in DNA methylation compared to 3-d 706 
TTX exposed experimental group (B). Finally, an overlap schematic (C) is presented to 707 
represent the relationship between DNA methylation and mRNA expression of key 708 
transcripts (arbitrary units).  709 
 710 
 711 
 712 
Common Abbreviations 713 
CSA, cross-sectional area; H&E, hematoxylin and eosin; TA, tibialis anterior; TTX, 714 
tetrodotoxin; nAchR, nicotinic acetyl choline receptor; MyoG, myogenin; Hdac4, Histone 715 
Deacetylase 4; Trim63 / Murf1, tripartite motif containing 63 or Muscle RING-finger 716 
protein-1; Ampd3, adenosine monophosphate deaminase 3; Chrna1, acetylcholine receptor 717 
subunit alpha 1; bHLH muscle specific basic helix-loop-helix; MRFs, myogenic regulatory 718 
factors; Fbxo32 / MaFbx, F-Box Protein 32 / muscle-specific F-box protein; HRM, High 719 
Resolution Melting 720 
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Table 1. Primer Assay Design for Reverse Transcription Quantitative Real Time 
Polymerase Chain Reaction 
 
Gene 
Name 
 
Accession 
No. 
  
Primer Sequence 
 
Primer 
Length 
 
Optimum 
Annealing 
Temperature 
 
 Product 
Length 
 
Trim63 
 
NM_0809
03 
 
F 
 
GGAGGAGTTTACTGAAGAGG  
 
20 
 
61 
 
180 
 
R 
 
GACACACTTCCCTATGGTGC  
 
20 
 
Fbxo32 
 
NM_1335
21 
 
F 
 
CTTGTCTGACAAAGGGCAGC  
 
20 
 
61 
 
184 
 
R 
 
 TGAAAGTGAGACGGAGCAGC  
 
20 
 
Ampd3 
 
NM_0315
44 
 
F 
 
ACGCTTGCTGGTCGGTTTAG 
 
20 
 
60 
 
96 
 
R 
 
TGGCTTCCTTCTGTCCGATG  
 
20 
 
Hdac4 
 
XM_3436
29.4 
 
F 
 
GCAGCCAAACTTCTCCAGCA  
 
20 
 
61 
 
212 
 
R 
 
TTGACATTGAAACCCACGCC 
 
20 
 
MyoG 
 
NM_0171
15.2 
 
F 
 
GCCATCCAGTACATTGAGCG  
 
20 
 
61 
 
267 
 
R 
 
CATATCCTCCACCGTGATGC 
 
20 
 
Chrna1 
 
NM_0244
85.1 
 
F 
 
 TGTCATCAACACACACCACC 
 
20 
 
61 
 
269 
 
R 
 
CTGCAATGTACTTCACACCC  
 
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Description of targeted DNA methylation assays for loci specific 
pyrosequencing analysis 
 
 
Gene 
 
CpG 
 
Position from 
ATG codon 
 
Position 
from TSS 
 
Chromatin Location 
 
Assay Sequence 
      
 
Myogenin 
  
-280 to -251 
 
-247 to -
218 
 
Chr13: 51126212-51126241 
 
 
AGTYGAYGGTTTTTYGATTYGTGTAT
AGGAGTYGTTTGGG 
 CpG-9 -280 -247 Chr13:51126212 
 CpG-8 -277 -244 Chr13:51126215 
 CpG-7 -269 -236 Chr13:51126223 
 CpG-6 -264 -231 Chr13:51126228 
 CpG-5 -251 -218 Chr13:51126241 
 
Trim 63 
  
-63 to +30 
 
+40 to 
+133 
 
Chr5: 152533388-
152533481 
 
ATTYGAGTGGGATTTTTTTTATTYGG
TGTGAYGTAGGTGGAAGAGATAGTY
GTAGTTTYGAAGTAATATGGATTATA
AATTTGGTTTGATTTYGGAYGGAAAT
G 
 CpG-5 -64 40 Chr5:152533388 
 CpG-4 -44 60 Chr5:152533408 
 CpG-3 -36 68 Chr5:152533416 
 CpG-2 -17 87 Chr5:152533435 
 CpG-1 -9 95 Chr5:152533443 
 CpG1 26 129 Chr5:152533447 
 CpG2 30 133 Chr5:152533481 
 
Ampd 3 
  
-559 to -555 
 
-540 to -
536 
 
Chr1:175585557-
175585561 
 
GYGGGYGTATGGGTG 
 CpG-10 -559 -540 Chr1:175585557 
 CpG-9 -555 -536 Chr1:175585561 
 
Fbxo 32 
  
-519 to -465 
 
-322 to -
268 
 
Chr7: 98098536-98098590 
 
TAYGTTYGATAGGGGAGTAGGGGA
GGTGTAAGAGGTGTTAGGGTATYGA
GGGTTAGYGGGATATTTGG 
 
 CpG-49 -519 -322 Chr7:98098590 
 CpG-48 -515 -318 Chr7:98098586 
 CpG-47 -475 -278 Chr7:98098546 
 CpG-46 -465 -268 Chr7:98098536 
 
Chrna 1 
  
-198 to -240 
 
-137 to -
179 
 
Chr3: 60460861-60460903 
 
TCRACTCATATTAAACRTAAACCRTA
TAAAAATCTACATAAATCRTAAACCA
AAAAC 
 
 CpG-7 -240 -179 Chr3:60460903 
 CpG-6 -219 -158 Chr3:60460882 
 CpG-5 -212 -151 Chr3:60460875 
 CpG-4 -198 -137 Chr3:60460861 
 
 
 
 
 
 
Table 3. HDAC4 DNA Methylation via High Resolution Melting Polymerase Chain 
Reaction 
 
 
Gene 
Name 
 
CpG 
No. 
 
Gene Globe 
Cat No. 
 
Chromatin 
Location 
 
Primer Sequence 
 
Product Length 
 
 
 
 
 
 
Hdac4 
 
1 
 
PM00599046 
 
 
Chr9:91389151
-91391341 
 
 
GGGCGCGCAAGAGCGCAGACTGTGA
CGGGGGCCCGGT 
 
190 
 
2 
 
PM00599053 
 
Chr9:91390077
-91391147 
 
GCGCCCGCGAAGCGGGGGTGGCTGT
TGGGCTATTGTAGGGCGGA 
 
138 
 
3 
 
PM00599060 
 
Chr9:91389052
-91391220 
 
GCTAGCGCCTGGAGAGTCCTCGGTA
CGCCCCGC 
 
168 
 
4 
 
PM00599067 
 
Chr9:91389477
-91391621 
 
GCTTTGGGTCGCCGCCACCGCGTCCC
GGT 
 
144 
 
5 
 
PM00599074 
 
Chr9:91389472
-91391621 
 
CGTTGCTGTGGCGGAGGTGTAGGCT
TTGGGTCGCCGCCACCGCGTCCCG 
 
149 
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